Loading...
CYTO.F logo

Altamira Therapeutics Ltd.OTCPK:CYTO.F Stock Report

Market Cap US$406.4k
Share Price
US$0.06
US$5.29
98.9% undervalued intrinsic discount
1Y-39.8%
7D-22.0%
1D
Portfolio Value
​
View

Altamira Therapeutics Ltd.

OTCPK:CYTO.F Stock Report

Market Cap: US$406.4k

Altamira Therapeutics (CYTO.F) Stock Overview

Operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. More details

CYTO.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Rewards

Earnings have grown 4.9% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($406K)

Latest financial reports are more than 6 months old


CYTO.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Altamira Therapeutics Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Altamira Therapeutics
Historical stock prices
Current Share PriceUS$0.06
52 Week HighUS$0.15
52 Week LowUS$0.05
Beta2.84
1 Month Change-26.59%
3 Month Change-16.83%
1 Year Change-39.83%
3 Year Change-99.59%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Seeking Alpha • Sep 13

Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID

Altamira Therapeutics (NASDAQ:CYTO) on Tuesday said it had completed enrollment in its clinical trial assessing the safety, tolerability and efficacy of its Bentrio nasal spray to treat acute COVID-19. The trial, called COVAMID, reached its extended enrollment target of 160 confirmed subjects, CTYO said in a statement. Bentrio is an over-the-counter drug-free nasal spray designed to protect against airborne viruses and allergens. The company expects data from the COVAMID trial during Q4 2022. CYTO in late Aug. said it was advancing discussions on divesting or spinning off its Bentrio nasal spray as well as its AM-125 nasal spray for vertigo. CYTO stock -4.8% to $0.37 in afternoon trading.
Seeking Alpha • Aug 30

Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio

Altamira Therapeutics (NASDAQ:CYTO) said it is advancing discussions on divesting or spinning off its Bentrio nasal spray as well as AM-125, an intranasal form of betahistine for vertigo. The company noted it had Bentrio sales of $1.3M in the first half of the year. Altamira (CYTO) also said it is continuing it plan to focus on RNA treatments. Its most advanced candidates in this area, both in the preclinical stages and siRNAs, are AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis. Altamira (CYTO) said it will report in 1H 2022 results in early October.
Seeking Alpha • Jul 25

Altamira starts development program for potential arthritis therapy

Altamira Therapeutics (NASDAQ:CYTO) said it began a development program for a rheumatoid arthritis (RA) therapy with the aim of licensing it at a later stage as per its partnering strategy. The drug product, which will be developed under the project code AM-411, is based on Altamira's proprietary OligoPhoreTM delivery platform and siRNA targeting NF-κB, the company added in a July 25 press release. "OligoPhore is delivering siRNA specifically to inflamed tissues, which in the case of RA is primarily the inflamed joints. The treatment is thus sparing non-inflamed tissues and avoiding the systemic side effects frequently observed with current treatment options," said Altamira's Chief Development Officer  Covadonga Pañeda. CYTO -2.31% premarket to $0.41
Seeking Alpha • Jul 19

Altamira announces peer-reviewed publication on mRNA delivery platform

The shares of the nano-cap biotech Altamira Therapeutics (NASDAQ:CYTO) jumped ~56% in the pre-market Tuesday after the company announced the publication of a peer-reviewed article that highlighted the potential of its mRNA delivery platform. The article published in the journal Pharmaceutics was based on an independently funded study run by a Korean research group on various mRNA delivery platforms. The analysis included Altamira’s (CYTO) SemaPhore platform, which is based on the p5RHH, a cell-penetrating peptide (CPP). “Our results showed that amphipathic CPPs exhibited more effective uptake and transfection capacity than cationic CPPs. Notably, the p5RHH/mRNA complexes could be selected for potential cancer therapy,” the researchers wrote. The announcement of another peer-reviewed publication on the company’s OligoPhore RNA delivery platform sent Altamira (CYTO) shares higher last week. However, the maker of Bentrio anti-microbial nasal spray has lost ~84% of its value over the past 12 months, as shown in this graph.
Seeking Alpha • Jul 12

Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform

Altamira Therapeutics (NASDAQ:CYTO) on Tuesday announced peer-reviewed publication of data that showed that its RNA delivery platform was an effective treatment for abdominal aortic aneurysm (AAA) in rodents. The peer-reviewed article was titled "Peptide-siRNA nanoparticles targeting NF-κB p50 mitigate experimental abdominal aortic aneurysm (AAA) progression and rupture" and was published in the journal Biomaterials Advances. CYTO stock had gained 9.5% to $0.53 in morning trading. The article, which was co-authored by CYTO's chief scientific officer, covered a preclinical study conducted by a research group at Washington University that found that CYTO's peptide-based OligoPhore delivery platform using siRNA was effective in mitigating AAA progression and rupture in a rodent model study. AAA is a condition characterized by the enlargement or swelling of the aorta - the main blood vessel that delivers blood to the body - at the abdomen. It can be life threatening if the swelling bursts.
Seeking Alpha • Jun 21

Auris Medical shares rise on OligoPhore Lymphoma study results

Auris Medical Holding shares jump ([[EARS]] +8.1%) after the company announced the publication of positive results from an in vivo study demonstrating "significant inhibition of tumor growth" by siRNA knock-down of NF-κB employing its OligoPhore technology in Adult T-cell Leukemia Lymphoma ((ATLL)), a rare and aggressive type of non-Hodgkin’s lymphoma.NF-κB is a protein complex that plays a key role in regulating the immune response to infection and is critical for tumor progression in ATLL.The study showed rapid delivery of siRNA to the tumor and
Analysis Article • Dec 09

Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

Shareholder Returns

CYTO.FUS PharmaceuticalsUS Market
7D-22.0%-1.5%2.3%
1Y-39.8%36.8%25.5%

Return vs Industry: CYTO.F underperformed the US Pharmaceuticals industry which returned 35.1% over the past year.

Return vs Market: CYTO.F underperformed the US Market which returned 24.8% over the past year.

Price Volatility

Is CYTO.F's price volatile compared to industry and market?
CYTO.F volatility
CYTO.F Average Weekly Movement58.6%
Pharmaceuticals Industry Average Movement10.2%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: CYTO.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CYTO.F's weekly volatility has increased from 51% to 59% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200311Thomas Meyeraltamiratherapeutics.com

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; and AM-125 that is in post phase II clinical trial for the intranasal treatment of vertigo. The company was formerly known as Auris Medical Holding Ltd.

Altamira Therapeutics Ltd. Fundamentals Summary

How do Altamira Therapeutics's earnings and revenue compare to its market cap?
CYTO.F fundamental statistics
Market capUS$406.37k
Earnings (TTM)-US$5.65m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.1x
P/E Ratio

Is CYTO.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CYTO.F income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$5.65m
Earnings-US$5.65m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.99
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio10.9%

How did CYTO.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/16 07:16
End of Day Share Price 2026/06/16 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Altamira Therapeutics Ltd. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Liisa BaykoCitizens JMP Securities, LLC
Hunter DiamondDiamond Equity Research LLC
Maxim JacobsEdison Investment Research